Results 141 to 150 of about 414,372 (151)

Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial

Diabetes Care, 2017
Keith Bowering, Bruce W Bode
exaly  

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

Clinical Pharmacokinetics, 2016
Eric Zijlstra, Ulrike Hövelmann, Tim Heise   +2 more
exaly  

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

Diabetes Care, 2017
Christophe De Block, Simon Heller, Athena Philis-Tsimikas   +2 more
exaly  

Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide

Pharmaceutical Research, 2019
Jeppe Sturis, Hanne H.F. Refsgaard, Jonas Kildegaard   +2 more
exaly  

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

Diabetologia, 2004
Pierre Fontaine, M A Gall
exaly  

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers

European Journal of Clinical Pharmacology, 1999
Philip D Home, A Lindholm
exaly  

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

Diabetes Care, 2014
Gregory R Fulcher, Henriette Mersebach, Jens Sandahl Christiansen   +2 more
exaly  

Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes—The glargine and aspart study (GLASS)A randomised cross-over study

Diabetes Research and Clinical Practice, 2007
Paul G McNally, M J Davies
exaly  

Pharmacological Properties of Faster-Acting Insulin Aspart

Current Diabetes Reports, 2017
Torben Biester, Olga Kordonouri, Thomas Danne   +2 more
exaly  

Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers

Diabetes Research and Clinical Practice, 2000
Masafumi Matsuda, Kohei Kaku, K Kaku
exaly